Bright Way Biosciences: Asset impairment provision of 78.1142 million yuan is booked for the fiscal year 2025.

Mingde Biotechnology announced that, according to relevant regulations, the company will conduct impairment tests on assets with impairment indicators as of December 31, 2025. The company plans to provide a total of RMB 78.1142 million for various asset impairments in 2025, including RMB 64.7913 million for credit impairment losses and RMB 13.3230 million for asset impairment losses. This provision will reduce the total profit for 2025 by RMB 78.1142 million, reduce the net profit attributable to common shareholders of the listed company by RMB 32.7505 million, and reduce the net assets attributable to the owners of the parent company by RMB 32.7505 million.